Cancer Therapeutic Procedure
Dispatch Bio Launches with $216M and CAR-T Pioneer Carl June to Advance Universal Solid Tumor Immunotherapy
Dispatch Bio; solid tumors; immunotherapy; CAR-T; Carl June; Series A funding; Flare platform; Parker Institute for Cancer Immunotherapy; ARCH Venture Partners; universal cancer treatment
Sino Biopharm Acquires Merck’s PD-1xVEGF Bispecific Partner LaNova for up to $951M
Sino Biopharm; LaNova Medicines; acquisition; Merck; PD-1xVEGF bispecific antibody; cancer therapy; Chinese pharma; $951 million deal
BioNTech Halts Cell Therapy Manufacturing at Maryland Site, Lays Off Dozens
BioNTech; cell therapy; Maryland; layoffs; CAR-T; BNT211; Gaithersburg; manufacturing facility; cancer therapy; clinical trial
BioNTech to Acquire CureVac in $1.25B All-Stock mRNA Deal
BioNTech; CureVac; acquisition; mRNA vaccines; cancer treatment; all-stock deal; Germany; biotechnology; oncology; COVID-19 vaccine
Pfizer Pays $1.25B Upfront to 3SBio, Joining the PD-1 x VEGF Race with Licensing Deal for SSGJ-707
Pfizer; 3SBio; PD-1/VEGF bispecific antibody; SSGJ-707; oncology; upfront payment; licensing deal; cancer therapy; China; drug development
FDA to Decide on Merck’s Subcutaneous Keytruda in September 2025
Subcutaneous Keytruda, FDA decision, September 23, 2025, Merck & Co., cancer treatment, PDUFA date
ImmunoPrecise Antibodies Secures $8-10M Partnership for Novel Cancer Therapeutics Development
ImmunoPrecise Antibodies, Antibody-Drug Conjugates (ADCs), bispecific antibodies, cancer treatment, AI-driven discovery, B-cell Select™ technology
Callio Therapeutics Debuts with $187M to Develop Next-Generation Multi-Payload ADCs for Cancer
Multi-payload ADCs, antibody-drug conjugates, oncology, HER2-targeted therapy, dual-payload technology, cancer treatment, biotechnology startup
FDA Approves Ono Pharmaceutical’s Romvimza for Rare Joint Tumor
Romvimza, tenosynovial giant cell tumor (TGCT), FDA approval, Ono Pharmaceutical, Deciphera acquisition, kinase inhibitor, rare cancer treatment
Eli Lilly Expands Pipeline with Strategic Deals in MASH and Cancer Therapies
Eli Lilly, OliX Pharmaceuticals, AdvanCell, MASH, targeted alpha therapies, radiopharmaceuticals, RNA interference, cardiometabolic diseases, cancer treatment